Retatrutide (10 mg Vial) Dosage Protocol
Research guide for gradual escalation dosing and reconstitution procedures for Retatrutide, a novel triple agonist investigated for weight management and metabolic improvement.
Quickstart Highlights
Retatrutide functions as an innovative triple agonist simultaneously targeting GLP-1, GIP, and glucagon receptors, developed for weight management and metabolic enhancement. Operating through concurrent activation of three hormone receptors governing appetite, insulin secretion, and energy expenditure, this compound features a ~6-day half-life permitting once-weekly dosing.
- Reconstitute: Add 2.0 mL bacteriostatic water → 5.0 mg/mL concentration
- Weekly dosing schedule: 2 mg → 4 mg → 8 mg → 12 mg over 13+ weeks
- Easy measuring: At 5.0 mg/mL, 1 unit on U-100 syringe = 50 mcg
- Storage: Lyophilized: −20 °C (−4 °F) or colder; Reconstituted: 2–8 °C (35.6–46.4 °F), use within 2–4 weeks
Dosing & Reconstitution Guide
Standard Gradual Titration for weekly subcutaneous administration
Weekly Subcutaneous Protocol (2 mL = 5.0 mg/mL)
| Weeks | Weekly Dose | Syringe Volume (U-100) | mL Equivalent |
|---|---|---|---|
| 1–4 | 2,000 mcg (2 mg) | 40 units | 0.40 mL |
| 5–8 | 4,000 mcg (4 mg) | 80 units | 0.80 mL |
| 9–12 | 8,000 mcg (8 mg) | 160 units | 1.60 mL* |
| 13+ | 12,000 mcg (12 mg) | 240 units | 2.40 mL* |
Administration: Once weekly, subcutaneous injection. *For doses exceeding 1.0 mL, either reconstitute a second vial or split across multiple injection sites.
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water using a sterile syringe
- Inject slowly down the vial wall to avoid foaming
- Gently swirl/roll until fully dissolved (do not shake vigorously)
- Label with reconstitution date
- Refrigerate at 2–8 °C (35.6–46.4 °F), protected from light
- Use within 2–4 weeks
Result: 5.0 mg/mL concentration
Storage Guidelines
- Lyophilized: −20 °C (−4 °F), dry/dark conditions
- Reconstituted: 2–8 °C (35.6–46.4 °F); do NOT freeze
- Shelf life: 28 days post-reconstitution
Key Administration Notes
- Rotate injection sites to prevent lipohypertrophy
- Gastrointestinal effects common initially; titration minimizes them
- Document weekly dose, date, and injection site
- Use sterile syringes; dispose in sharps container
- Allow vials to reach room temperature before opening
⚠️ Research & Educational Purposes Only
This information is provided for research and educational purposes only. Peptides discussed are intended for laboratory research use only and are not approved for human consumption. Always consult qualified healthcare professionals for medical advice. Individual results may vary. This is not medical advice.